European public procurement and grants data from official registers · Data as of 18 November 2026; updated daily.

Tenders

Oncology drug tenders in Czechia

Oncology drug tenders in Czechia: 2,950 listed on GranTender since 2024; 32 open now. The median awarded contract value is about €410,000 (1,407 contracts with a stated value). Buyers with the most tenders: Fakultní nemocnice Olomouc (271), Fakultní nemocnice Ostrava (248) and Fakultní Thomayerova nemocnice (107); suppliers with the most contract awards: ROCHE s.r.o. (442), Merck Sharp & Dohme s.r.o. (235) and Janssen-Cilag s.r.o. (177). Sources: Registr smluv, ISVZ (NIPEZ) and TED. In 2025 the median contract value was €10,000; 70% of contracts drew a single bid (3.9 bids on average). Data as of 18 November 2026; updated daily.

Tenders
2,950
Open tenders
32
Awards
4,535
Awarded value awarded
€2,186,580,861
Awarded value contract
€1,235,717,225
Awarded value framework ceiling
€955,641,053
Median contract value contract
≈ €11,000
Median contract value awarded
≈ €410,000
Median contract value framework ceiling
≈ €430,000
Average bids per contract
3.8
Tenders in 2025
981 -3% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

TenderBuyerEstimated valueStatusPublished
Léčivé přípravky s obsahem amivantamabuFakultní nemocnice Hradec KrálovéCZK 2,706,000 (≈ €111,376)Open16 November 2026
Cytostatikum, inhibitor tyrozinkináz s účinnou látkou CrizotinibumFakultní nemocnice OstravaCZK 7,962,967 (≈ €327,748)Open13 November 2026
Léčivý přípravek s účinnou látkou MelphalanumFakultní nemocnice OstravaCZK 1,850,003 (≈ €76,144)Open13 November 2026
Cytostatikum s účinnou látkou FluorouracilumFakultní nemocnice OstravaCZK 4,135,588 (≈ €170,217)Open13 November 2026
Parenterální cytostatikum s účinnou látkou IfosfamidumFakultní nemocnice OstravaCZK 6,288,884 (≈ €258,844)Open13 November 2026
Imunosupresiva - inhibitor kalcineurinu II. - cyklosporinInstitut klinické a experimentální medicínyCZK 13,999,000 (≈ €576,185)Open11 November 2026
LP s obsahem siponimodu - sdružený nákup 2026Fakultní nemocnice OlomoucCZK 106,969,190 (≈ €4,402,749)Open11 November 2026
LP s obsahem ponatinibu 2026 - sdružený nákupFakultní nemocnice OlomoucCZK 27,577,746 (≈ €1,135,074)Open10 November 2026
Léčivé přípravky s obsahem irinotekanu - Sdružený nákup 2026Fakultní nemocnice Hradec KrálovéCZK 18,515,000 (≈ €762,060)Open30 October 2026
Léčivé přípravky s obsahem irinotekanu - Sdružený nákup 2026Fakultní nemocnice Hradec KrálovéCZK 18,515,000 (≈ €762,060)Open30 October 2026
Infliximab 120 mgÚstřední vojenská nemocnice - Vojenská fakultní nemocnice PrahaCZK 17,459,966 (≈ €718,635)Open26 October 2026
LP s obsahem bimekizumabu 2026Fakultní nemocnice OlomoucCZK 28,894,769 (≈ €1,189,281)Open26 October 2026
Infliximab 120 mgÚstřední vojenská nemocnice - Vojenská fakultní nemocnice PrahaCZK 17,459,966 (≈ €718,635)Open26 October 2026
LP s obsahem bimekizumabu 2026Fakultní nemocnice OlomoucCZK 28,894,769 (≈ €1,189,281)Open26 October 2026
Léčivé přípravky s obsahem venetoklaxuFakultní nemocnice Hradec KrálovéCZK 242,757,777 (≈ €9,991,677)Open23 October 2026
Léčivé přípravky s obsahem venetoklaxuFakultní nemocnice Hradec KrálovéCZK 242,757,777 (≈ €9,991,677)Open23 October 2026
Dodávky léků – Léčivá látka amivantamab – ATC L01FX18Fakultní Thomayerova nemocniceCZK 41,489,536 (≈ €1,707,669)Open22 October 2026
Dodávky léků – Léčivá látka lenvatinib – ATC L01EX08Fakultní Thomayerova nemocniceCZK 26,231,418 (≈ €1,079,660)Open22 October 2026
Dodávky léků – Léčivá látka lenvatinib – ATC L01EX08Fakultní Thomayerova nemocniceCZK 26,231,418 (≈ €1,079,660)Open22 October 2026
Dodávky léků – Léčivá látka amivantamab – ATC L01FX18Fakultní Thomayerova nemocniceCZK 41,489,536 (≈ €1,707,669)Open22 October 2026

Latest tenders

TenderBuyerEstimated valueStatusPublished
Léčivé přípravky s obsahem amivantamabuFakultní nemocnice Hradec KrálovéCZK 2,706,000 (≈ €111,376)Open16 November 2026
Cytostatikum, inhibitor tyrozinkináz s účinnou látkou CrizotinibumFakultní nemocnice OstravaCZK 7,962,967 (≈ €327,748)Open13 November 2026
Léčivý přípravek s účinnou látkou MelphalanumFakultní nemocnice OstravaCZK 1,850,003 (≈ €76,144)Open13 November 2026
Cytostatikum s účinnou látkou FluorouracilumFakultní nemocnice OstravaCZK 4,135,588 (≈ €170,217)Open13 November 2026
Parenterální cytostatikum s účinnou látkou IfosfamidumFakultní nemocnice OstravaCZK 6,288,884 (≈ €258,844)Open13 November 2026
Imunosupresiva - inhibitor kalcineurinu II. - cyklosporinInstitut klinické a experimentální medicínyCZK 13,999,000 (≈ €576,185)Open11 November 2026
LP s obsahem siponimodu - sdružený nákup 2026Fakultní nemocnice OlomoucCZK 106,969,190 (≈ €4,402,749)Open11 November 2026
LP s obsahem ponatinibu 2026 - sdružený nákupFakultní nemocnice OlomoucCZK 27,577,746 (≈ €1,135,074)Open10 November 2026
Léčivé přípravky s obsahem irinotekanu - Sdružený nákup 2026Fakultní nemocnice Hradec KrálovéCZK 18,515,000 (≈ €762,060)Open30 October 2026
Léčivé přípravky s obsahem irinotekanu - Sdružený nákup 2026Fakultní nemocnice Hradec KrálovéCZK 18,515,000 (≈ €762,060)Open30 October 2026
Infliximab 120 mgÚstřední vojenská nemocnice - Vojenská fakultní nemocnice PrahaCZK 17,459,966 (≈ €718,635)Open26 October 2026
LP s obsahem bimekizumabu 2026Fakultní nemocnice OlomoucCZK 28,894,769 (≈ €1,189,281)Open26 October 2026
Infliximab 120 mgÚstřední vojenská nemocnice - Vojenská fakultní nemocnice PrahaCZK 17,459,966 (≈ €718,635)Open26 October 2026
LP s obsahem bimekizumabu 2026Fakultní nemocnice OlomoucCZK 28,894,769 (≈ €1,189,281)Open26 October 2026
Léčivé přípravky s obsahem venetoklaxuFakultní nemocnice Hradec KrálovéCZK 242,757,777 (≈ €9,991,677)Open23 October 2026
Léčivé přípravky s obsahem venetoklaxuFakultní nemocnice Hradec KrálovéCZK 242,757,777 (≈ €9,991,677)Open23 October 2026
Dodávky léků – Léčivá látka amivantamab – ATC L01FX18Fakultní Thomayerova nemocniceCZK 41,489,536 (≈ €1,707,669)Open22 October 2026
Dodávky léků – Léčivá látka lenvatinib – ATC L01EX08Fakultní Thomayerova nemocniceCZK 26,231,418 (≈ €1,079,660)Open22 October 2026
Dodávky léků – Léčivá látka lenvatinib – ATC L01EX08Fakultní Thomayerova nemocniceCZK 26,231,418 (≈ €1,079,660)Open22 October 2026
Dodávky léků – Léčivá látka amivantamab – ATC L01FX18Fakultní Thomayerova nemocniceCZK 41,489,536 (≈ €1,707,669)Open22 October 2026

Competition and prices

In 2025, half of the contracts were worth between €4,900 and €210,000, with a median of €10,000 (795 contracts with a stated contract value). Contracts drew 3.9 bids on average (median 1) and 70% drew a single bid — based on 1,140 contracts with a known number of bids. Compared with 2024, in 2025 the median value rose 37% and the share of single-bid contracts rose from 66% to 70%. The usual procedures: open procedure (75%), other procedures (22%), negotiation without a call for competition (2%) — of 1,318 tenders with a stated procedure.

The most contracts went to ROCHE s.r.o. (442), Merck Sharp & Dohme s.r.o. (235) and Janssen-Cilag s.r.o. (177) — together 19% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
20241,323€7,300 (contract value)€3,700 – €16,0003.866% (622)
20251,728€10,000 (contract value)€4,900 – €210,0003.970% (1,140)
2026 (so far)1,325€12,000 (contract value)€5,800 – €460,0003.770% (836)
All years4,459€10,000 (contract value)€4,900 – €230,0003.870% (2,632)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 70% of the 2,120 contracts with a known number of bids had a single bid; the median was 1 bid. The number of bids is known for 2,120 of the 3,254 contracts from procedures with competition.

Buyers who often get few offers

The buyers below usually received one or two offers per contract — an offer from you would stand out.

In the last 12 months, 0 companies won their first contract in our records here — 0% of the 603 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33652000 Antineoplastic and immunomodulating agents

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Oncology and immunomodulating drugs in neighbouring countries

Today, 16 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon3

ExpectedBuyerWhatWhy we expect itConfidence
now – Dec 2026
contract ends
Fakultní nemocnice BrnoOncology and immunomodulating drugs
Pomalidomid - sdružený nákup III
The current contract with ViaPharma s.r.o. ends on 20 January 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 09/2024
high
Jan – Jun 2027
contract ends
Nemocnice Boskovice s.r.oOncology and immunomodulating drugs
Dodávky léčivých přípravků s účinnou látkou adalimumab, ATC skupiny L04AB04, pro Nemocnici Boskovice s.r.o.
Typical value: ≈ €30,000
The current contract with PHOENIX lékárenský velkoobchod, s.r.o. ends on 12 July 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 05/2024
medium
Feb – Jul 2027
contract ends
Krajská nemocnice T. Bati, a. s.Oncology and immunomodulating drugs
Biologická léčba 2026 II
Typical value: ≈ €20,000
The current contract with Alliance Healthcare s.r.o. ends on 13 August 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 06/2026
high

Forecast from public data, not an announcement. Methodology.

Market reports

Oncology and immunomodulating drugs by city

Oncology and immunomodulating drugs in other countries

Oncology and immunomodulating drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Which oncology drug tenders in Czechia are open now?
32 of the 2,950 oncology drug tenders in Czechia listed on GranTender are open for bids. For example: Léčivé přípravky s obsahem amivantamabu; Cytostatikum, inhibitor tyrozinkináz s účinnou látkou Crizotinibum; Léčivý přípravek s účinnou látkou Melphalanum.
Where can I find oncology drug tenders in Czechia?
GranTender lists them in one place, from Registr smluv, ISVZ (NIPEZ) and TED, with their buyers, winners and contract values; 32 are open now. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most oncology drug tenders in Czechia?
By number of contracts won: ROCHE s.r.o. (442), Merck Sharp & Dohme s.r.o. (235), Janssen-Cilag s.r.o. (177).
Which buyers publish the most oncology drug tenders in Czechia?
By number of tenders: Fakultní nemocnice Olomouc (271), Fakultní nemocnice Ostrava (248), Fakultní Thomayerova nemocnice (107).
Which CPV codes belong to “Oncology and immunomodulating drugs”?
33652000 Antineoplastic and immunomodulating agents; plus tenders without a usable CPV code whose title names the topic.
How many bids do oncology drug tenders in Czechia receive on average?
In 2025, contracts drew 3.9 bids on average (median 1) and 70% drew a single bid — based on 1,140 contracts with a known number of bids.
How much are contracts for oncology drug tenders in Czechia worth?
In 2025, half of the contracts were worth between €4,900 and €210,000, with a median of €10,000 (795 contracts with a stated contract value). Compared with 2024, in 2025 the median value rose 37% and the share of single-bid contracts rose from 66% to 70%.
Which procedures are used for oncology drug tenders in Czechia?
The usual procedures: open procedure (75%), other procedures (22%), negotiation without a call for competition (2%) — of 1,318 tenders with a stated procedure.
Which buyers get few offers in oncology drug tenders in Czechia?
Since 1 November 2024, these buyers usually received one or two offers per contract: Fakultní nemocnice Olomouc (median 1 bid over 325 contracts), Fakultní Thomayerova nemocnice (median 1 bid over 156 contracts) and Revmatologický ústav (median 1 bid over 114 contracts). Since 1 November 2024, 70% of the 2,120 contracts with a known number of bids had a single bid; the median was 1 bid.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.